Add to ORKGThe doxorubicin plus cyclophosphamide (AC) and cyclophosphamide, methotrexate and fluorouracil (CMF) regimens were used as the standard adjuvant chemotherapy regimens for breast cancer (Fisher et al.
The aim of the study was to evaluate the feasibility of tailored and dose-dense epirubicin and cyclo...
Non-pegylated liposomal doxorubicin in combination with cyclophosphamide or docetaxel as first-line ...
Purpose The PACS 01 trial compared six cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC...
Background: This study was designed to determine whether delivering neo-adjuvant chemotherapy at a h...
Uncertainty exists around the need to include an anthracycline if taxane-based adjuvant chemotherapy...
Background: This study was designed to determine whether delivering neo-adjuvant chemotherapy at a h...
Background: This study was designed to determine whether delivering neo-adjuvant chemotherapy at a h...
Background: This study was designed to determine whether delivering neo-adjuvant chemotherapy at a h...
Abstract BACKGROUND: This study was designed to determine whether delivering neo-adjuvant chemothera...
INTRODUCTION: Dose-dense therapies have had a major effect on reducing toxicity and improving outcom...
INTRODUCTION: Dose-dense therapies have had a major effect on reducing toxicity and improving outcom...
BACKGROUND: The optimal regimen for adjuvant breast cancer chemotherapy is undefined. We compared se...
Background: ABC trials established the use of non-anthracycline containing regimen, docetaxel and cy...
Background: Neoadjuvant chemotherapy with concurrent docetaxel, doxorubicin and cyclophosphamide is ...
Non-pegylated liposomal doxorubicin in combination with cyclophosphamide or docetaxel as first-line ...
The aim of the study was to evaluate the feasibility of tailored and dose-dense epirubicin and cyclo...
Non-pegylated liposomal doxorubicin in combination with cyclophosphamide or docetaxel as first-line ...
Purpose The PACS 01 trial compared six cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC...
Background: This study was designed to determine whether delivering neo-adjuvant chemotherapy at a h...
Uncertainty exists around the need to include an anthracycline if taxane-based adjuvant chemotherapy...
Background: This study was designed to determine whether delivering neo-adjuvant chemotherapy at a h...
Background: This study was designed to determine whether delivering neo-adjuvant chemotherapy at a h...
Background: This study was designed to determine whether delivering neo-adjuvant chemotherapy at a h...
Abstract BACKGROUND: This study was designed to determine whether delivering neo-adjuvant chemothera...
INTRODUCTION: Dose-dense therapies have had a major effect on reducing toxicity and improving outcom...
INTRODUCTION: Dose-dense therapies have had a major effect on reducing toxicity and improving outcom...
BACKGROUND: The optimal regimen for adjuvant breast cancer chemotherapy is undefined. We compared se...
Background: ABC trials established the use of non-anthracycline containing regimen, docetaxel and cy...
Background: Neoadjuvant chemotherapy with concurrent docetaxel, doxorubicin and cyclophosphamide is ...
Non-pegylated liposomal doxorubicin in combination with cyclophosphamide or docetaxel as first-line ...
The aim of the study was to evaluate the feasibility of tailored and dose-dense epirubicin and cyclo...
Non-pegylated liposomal doxorubicin in combination with cyclophosphamide or docetaxel as first-line ...
Purpose The PACS 01 trial compared six cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC...